Marketing Authorisation Holder Invented name Strength Pharmaceutical Form. Postinor 1500 Mikrogramm-Tablette
|
|
|
- Randell Curtis
- 6 years ago
- Views:
Transcription
1 Annex I List of the names, pharmaceutical form, strengths of the medicinal products, route of, marketing authorisation holders in the Member States 1
2 Levonorgestrel-containing emergency contraceptive medicinal products Member State Austria Austria Austria Austria Austria Belgium 15. rue Béranger Velvian GmbH Carl-Zeiss-Ring Ismaning Velvian GmbH Carl-Zeiss-Ring Ismaning Sandoz N.V. Telecom Gardens Medialaan Vilvoorde Belgium Postinor 1500 Mikrogramm-Tablette Vikela 750 Mikrogramm mg Tablet Oral use Tabletten Vikela 1,5 Milligramm- Tablette Velafam 1,5 mg Tabletten Velafam 750 Mikrogramm 0.75 mg Tablet Oral use Tabletten Levodonna 2
3 Belgium Belgium Belgium Belgium Bulgaria Bulgaria Bulgaria 15. rue Béranger Norlevo 0.75 mg Tablet Oral use Norlevo Postinor Postinor 0.75 mg Tablet Oral use Escapelle Ramonna Postinor-Duo 0.75 mg Tablet Oral use 3
4 Bulgaria Bulgaria Croatia Croatia Cyprus Cyprus Laboratorios Leon Farma SA Poligono Industrial Navatejera, La Vallina s/n, Villaquilambre,Leon Laboratorios Leon Farma SA Poligono Industrial Navatejera, La Vallina s/n, Villaquilambre,Leon Arenda d.o.o., Medarska ulica 56b Zagreb Croatia Sandoz d.o.o. Maksimirska 120 Zagreb Croatia Etiyone Melkidos 0.75 mg Tablet Oral use Vikela 1,5 mg tableta Escapelle Norlevo 0.75 mg Tablet Oral use Norlevo 4
5 Czech Republic Czech Republic Czech Republic Czech Republic Czech Republic Denmark Denmark Egis Pharmaceuticals PLC Keresztúri út H-1106 Budapest Laboratorios León Farma S.A. Calle La Vallina s/n Polígono Industrial Navatejera Navatejera - León Escapelle Postinor mg Tablet Oral use Ramonna Egianti 0,75 mg 0.75 mg Tablet Oral use Nopregy 1,5 mg tablety Norlevo 0.75 mg Tablet Oral use Norlevo 5
6 Denmark Estonia Estonia Estonia Estonia Estonia Estonia Sandoz A/S Edvard Thomsens Vej 14 DK-2300 København S Denmark Orivas UAB J.Jasinskio 16B LT Vilnius Sandoz Pharmaceuticals Verovškova Ljubljana Slovenia Actavis Group PTC ehf Reykjavikurvegi Hafnarfjördur Iceland Orivas UAB J.Jasinskio 16B LT Vilnius Levodonna RAMONNA ESCAPELLE LEVIDON 0.75 mg Tablet Oral use LEVODONNA LEVONORGESTREL 0.75 mg Tablet Oral use ACTAVIS ELISTREL 6
7 Finland Finland MYLAN SAS 117, allée des Parcs Saint-Priest Norlevo 0.75 mg Tablet Oral use Norlevo ANTHIA mg Tablet Oral use microgrammes, comprimé LEVONORGESTREL BIOGARAN 1500 microgrammes, comprimé LEVONORGESTREL MYLAN 1,5 mg, comprimé NORLEVO 1,5 mg, comprimé NORLEVO mg Tablet Oral use microgrammes, comprimé 7
8 VELVIAN GmbH Carl-Zeiss-Ring Ismaning VELVIAN GmbH Carl-Zeiss-Ring Ismaning Hexal Aktiengesellschaft Industriestr Holzkirchen VIKELA 1,5 mg, comprimé VIKELA mg Tablet Oral use microgrammes, comprimé Navela 0,75 mg Tabletten 0.75 mg Tablet Oral use Navela 1,5 mg Tabletten PiDaNa 1,5 mg Tablette Postinor 1500 Mikrogramm Tablette unofem HEXAL 1,5 mg Tabletten 8
9 Greece Greece Greece Laboratorios Leon Farma, SA Poligono Industrial Navatejera C/La Vallina s/n Navatejera - Villaquilambre Egis Pharmaceuticals PLC Keresztúri út H-1106 Budapest Actavis Group PTC ehf Reykjavikurvegi Hafnarfjördur Iceland Etiyone 1500 Mikrogramm Tabletten NORLEVO 0.75 mg Tablet Oral use NORLEVO POSTINOR Escapelle Empil 0,75 mg tabletta 0.75 mg Tablet Oral use Helibona 9
10 Iceland Iceland Iceland Ireland Ireland Ireland Rigesoft 0.75 mg Tablet Oral use Norlevo Norlevo 0.75 mg Tablet Oral use Postinor Levonelle 1500 microgram Tablet NORLEVO mg Tablet Oral use micrograms tablet NORLEVO 1.5 mg tablet 10
11 Ireland Italy Italy Italy Latvia Latvia Latvia Laboratorios Leon Farma, S.A. C/ Roa de la Vega 15, Leon Tyedra 1500 micrograms tablet NORLEVO 0.75 mg Tablet Oral use NORLEVO LONEL Escapelle 1,5 mg tablets Ramonna 1500 micrograms tablets Postinor-Duo mg Tablet Oral use micrograms tablets 11
12 Latvia Latvia Latvia UAB Orivas J. Jasinskio g. 16B LT Vilnius UAB Orivas J. Jasinskio g. 16B LT Vilnius Actavis Group PTC ehf Reykjavikurvegi Hafnarfjördur Iceland UAB Orivas J. Jasinskio g. 16B LT Vilnius UAB Orivas J. Jasinskio g. 16B LT Vilnius Elistrel 1500 micrograms tablets Levidon 750 micrograms 0.75 mg Tablet Oral use tablets Levonorgestrel Actavis 0.75 mg Tablet Oral use 750 micrograms tablets ESCAPELLE RAMONNA Elistrel Levidon 0.75 mg Tablet Oral use 12
13 Luxembourg Luxembourg Luxembourg Luxembourg UAB Inteli Generics Nord Šeimyniškių 3 LT Vilnius UAB Inteli Generics Nord Šeimyniškių 3 LT Vilnius Avodele 0.75 mg Tablet Oral use Avodele POSTINOR-DUO 0.75 mg Tablet Oral use Norlevo 0.75 mg Tablet Oral use Norlevo Postinor 0.75 mg Tablet Oral use Postinor 13
14 Norway Norway Norway Norway Poland Poland Portugal Sandoz A/S Edvard Thomsens Vej 14 DK-2300 København S Denmark Gedeon Richter Polska Sp. z o.o. 5 Ks. J. Poniatowskiego Street Grodzisk Mazowiecki Poland NORLEVO 0.75 mg Tablet Oral use NORLEVO POSTINOR Isteranda Escapelle tabletka 1500 mikrogramów Ramonna Norlevo 0.75 mg Tablet Oral use 14
15 Portugal Portugal Romania Romania Romania Slovak Republic Slovak Republic Gedeon Richter Romania S.A. Str. Cuza-Vodă nr Târgu Mureş Romania Norlevo Postinor ESCAPELLE RAMONNA POSTINOR mg Tablet Oral use micrograme ESCAPELLE Ramona 15
16 Slovak Republic Slovak Republic Slovenia Slovenia Slovenia Egis Pharmaceuticals PLC Keresztúri út H-1106 Budapest Actavis Group PTC ehf Reykjavikurvegi Hafnarfjördur Iceland Gyömrői út H-1103 Budapest Gyömrői út H-1103 Budapest CHIESI ESPAÑA, S.A. Plaça d Europa, planta L Hospitalet de Llobregat (Barcelona) EGIANTI 0,75 mg tablety 0.75 mg Tablet Oral use Helibona 1,5 mg Escapelle 1,5 mg tableta NORLEVO 1,5 mg tableta Ramonna 1,5 mg tableta Norlevo 750 microgramos 0.75 mg Tablet Oral use comprimidos 16
17 Sweden Sweden Sweden Sweden CHIESI ESPAÑA, S.A. Plaça d Europa, planta L Hospitalet de Llobregat (Barcelona) Actavis Group PTC ehf Reykjavikurvegi Hafnarfjördur Iceland Sandoz A/S Edvard Thomsens Vej 14 DK-2300 København S Denmark Norlevo 1500 microgramos comprimido Postinor 1500 microgramos comprimido Julirona 1,5 mg comprimido EFG NorLevo 0.75 mg Tablet Oral use NorLevo Levodonna Postinor 17
18 The Netherlands The Netherlands The Netherlands The Netherlands United Kingdom United Kingdom United Kingdom Perryment Ltd High street Esher, KT10 9QY Surrey Sandoz Limited Frimley Business Park Frimley, Camberley Surrey GU16 7SR NorLevo, tabletten 0,75 mg 0.75 mg Tablet Oral use NorLevo 1,5 mg, tabletten Postinor 1500 microgram, tablet Vikela, tabletten mg Tablet Oral use microgram Isteranda 1.5mg Tablets Upostelle 1500 Microgram Tablets Levonelle mg Tablet Oral use Microgram Tablet 18
19 United Kingdom Levonelle 1500 Microgram Tablet United Kingdom Levonelle One Step 1500 Microgram Tablet / Boots Emergency Contraceptive 1.5 mg Tablet United Kingdom Laboratorios Leon Farma SA Calle La Vallina S/N Poligono Industrial Navatejera Navatejera, Leon E Melkine 1.5mg Tablet 19
Marketing Authorisation Holder Invented name Strength Pharmaceutical Form. Postinor 1500 Mikrogramm-Tablette
Annex I List of the names, pharmaceutical form, strengths of the medicinal products, route of, marketing authorisation holders in the Member States 1 Levonorgestrel-containing emergency contraceptive medicinal
List of nationally authorised medicinal products
5 November 2015 EMA/230130/2016 Procedure Management and Committees Support Active substance: cabergoline Procedure no.: PSUSA/00000477/201503 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
Member State Marketing Authorisation Holder (Invented) Strength Pharmaceutical form Route of administration. Novartis Pharma NV
ANNEX I LIST OF THE INVENTED NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION AND MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES Member State Marketing Authorisation
List of nationally authorised medicinal products
3 December 2015 EMA/98477/2016 Procedure Management and Committees Support Active substance: acarbose Procedure no.: PSUSA/00000017/201503 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
Annex I. List of nationally authorised medicinal products and marketing authorisation applications
Annex I List of nationally authorised medicinal products and marketing authorisation applications 1 Annex IA: Medicinal products recommended for maintenance and marketing authorisation applications for
Smokefree Policies in Europe: Are we there yet?
Smokefree Policies in Europe: Are we there yet? 14 April 2015, 9:00 10:30am Rue de l Industrie 24, 1040 Brussels Permanent Partners: Temporary Partners: The research for the SFP Smokefree Map was partially
Orlistat EG 60 mg capsule, hard oral use. Orlistat EG 120 mg capsule, hard oral use. Orlistat Sandoz 60 mg capsule, hard oral use
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATIONS AND MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1 Belgium Belgium Belgium Belgium
WCPT COUNTRY PROFILE December 2017 SWEDEN
WCPT COUNTRY PROFILE December 2017 SWEDEN SWEDEN NUMBERS WCPT Members Practising physical therapists 11,043 Total number of physical therapist members in your member organisation 17,906 Total number of
WCPT COUNTRY PROFILE December 2017 HUNGARY
WCPT COUNTRY PROFILE December 2017 HUNGARY HUNGARY NUMBERS WCPT Members Practising physical therapists 727 Total number of physical therapist members in your member organisation 4,000 Total number of practising
WCPT COUNTRY PROFILE December 2017 SERBIA
WCPT COUNTRY PROFILE December 2017 SERBIA SERBIA NUMBERS WCPT Members Practising physical therapists 622 Total number of physical therapist members in your member organisation 3,323 Total number of practising
(Invented) Name. Crestor 5 mg Filmtabletten. Filmtabletten. Filmtabletten. Filmtabletten. Crestor 5 mg Film coated tablets Oral use
Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, route of and marketing authorisation holders in the Member s 1 Austria Austria Austria Austria Belgium Belgium Belgium
Member State Marketing autorisation Holder Invented Name Strength Pharmaceutical form Route of administration
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1 Member State Marketing autorisation Holder
(Invented) Name Strength Pharmaceutical Form. 3 mg/3 ml Solution for injection. Kytril 2 mg - Filmtabletten 2 mg Film-coated tablet Oral use
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTES OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1 Austria Austria Bulgaria Bulgaria
Annex I. List of medicinal products and presentations
Annex I List of medicinal products and presentations 1 Member State EU/EEA Marketing authorisation holder (Invented) Name Strength Pharmaceutical form Route of administration Austria Postinor 1500 1,5mg
Overview of drug-induced deaths in Europe - What does the data tell us?
Overview of drug-induced deaths in Europe - What does the data tell us? João Matias, Isabelle Giraudon, Julián Vicente EMCDDA expert group on the key-indicator Drug-related deaths and mortality among drug
Cross Border Genetic Testing for Rare Diseases
Cross Border Genetic Testing for Rare Diseases EUCERD Joint Action WP8 Helena Kääriäinen National Institute for Health an Welfare, Helsinki, Finland Starting point Possibilities and demand for genetic
(Invented) Name Strength Pharmaceutical form. Ergotop 10 mg - Tabletten. Ergotop 20 mg - Filmtabletten. Ergotop 30 mg - Filmtabletten
Annex I List of the names, pharmaceutical (s), strength(s) of the medicinal product(s), route(s) of, marketing authorisation holder(s) in the member states 1 Bulgaria Bulgaria Czech Republic Kwizda Pharma
PARALLELISM AND THE LEGITIMACY GAP 1. Appendix A. Country Information
PARALLELISM AND THE LEGITIMACY GAP 1 Appendix A Country Information PARALLELISM AND THE LEGITIMACY GAP 2 Table A.1 Sample size by country 2006 2008 2010 Austria 2405 2255 0 Belgium 1798 1760 1704 Bulgaria
Marketing Authorisation Holder (Invented) name Strength Pharmaceutical Form Route of administration Novartis Pharma GmbH
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES Member State EU/EEA Austria Austria Austria
Annex I. List of nationally authorised medicinal products and marketing authorisation applications
Annex I List of nationally authorised medicinal products and marketing authorisation applications 1 Annex IA: Medicinal products recommended for maintenance and marketing authorisation applications for
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT. DRYNOL 20 MG TABLETS bilastine
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT DRYNOL 20 MG TABLETS bilastine Read all of this leaflet carefully before you start taking this medicine because it contains important information for you only.
Amoxicillin 40 mg Clavulanic acid 10 mg. Clavulanic acid 10 mg. Clavulanic acid 10 mg. Clavulanic acid 10 mg
Annex I List of the names, pharmaceutical form, strength of the veterinary medicinal product, animal species, route of applicant/marketing authorisation holder in the member states 1/10 Member State EU/EEA
PACKAGE LEAFLET: INFORMATION FOR THE USER ALBUNORM 20% 200 g/l, Solution for infusion Human albumin
PACKAGE LEAFLET: INFORMATION FOR THE USER ALBUNORM 20% 200 g/l, Solution for infusion Human albumin Read all of this leaflet carefully before you start using this medicine. Keep this leaflet. You may need
European Collaboration on Dementia. Luxembourg, 13 December 2006
European Collaboration on Dementia Luxembourg, 13 December 2006 2005 Call for projects Special attention has also to be given to information and definition of indicators on neurodegenerative, neurodevelopment,
Monthly measles and rubella monitoring report
SURVEILLANCE REPORT Monthly measles and rubella monitoring report December 2018 Period covered: 1 November 2017 to 31 October 2018 Introduction This monitoring report is based on measles and rubella data
Member State Marketing Authorisation Holder Invented Name Strength Pharmaceutical Route of administration
ANNEX I LIST OF THE INVENTED NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION AND MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1 Member State Marketing
PACKAGE LEAFLET: INFORMATION FOR THE USER. Tetmodis 25 mg tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER Tetmodis 25 mg tablets {Tetrabenazine} Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need to read it again.
List of nationally authorised medicinal products
11 February 2016 EMA/255959/2016 Procedure Management and Committees Support Active substance: calcitonin salmon, synthetic analogue of eel calcitonin Procedure No.: PSUSA/00000494/201506 30 Churchill
Yersiniosis SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods. Epidemiology
SURVEILLANCE REPORT Annual Epidemiological Report for 2015 Yersiniosis Key facts In 2015, 26 countries reported 7 279 confirmed yersiniosis cases in the EU/EEA. The overall notification rate was 2.0 cases
List of nationally authorised medicinal products
7 July 2016 EMA/437334/2016 Procedure Management and Committees Support Division Active substance: Terazosin Procedure no.: PSUSA/00002895/201511 30 Churchill Place Canary Wharf London E14 5EU United Kingdom
ALCOHOL CONSUMPTION IN EUROPE; TRADITIONS, GENERATIONS, CULTURE AND POLICY
ALCOHOL CONSUMPTION IN EUROPE; TRADITIONS, GENERATIONS, CULTURE AND POLICY JACEK MOSKALEWICZ INSTITUTE OF PSCHIATRY AND NEUROLOGY WARSAW, POLAND THIRD EUROPEAN CONFERENCE ON ALCOHOL AND LAW ENFORCEMENT,
List of nationally authorised medicinal products
27 October 2016 EMA/719205/2016 Human Medicines Evaluation Division Active substance: ethinylestradiol / gestodene (except for transdermal application) Procedure no.: PSUSA/00001308/201603 30 Churchill
Emerging Risks Mapping of Activities in Member States. 67th Advisory Forum meeting, Utrecht, The Netherlands, 6 February 2018
Emerging Risks Mapping of Activities in Member States 67th Advisory Forum meeting, Utrecht, The Netherlands, 6 February 2018 BACKGROUND 67 th Advisory Forum Meeting, Utrecht, The Netherlands, 6 February
Department of Biological Standardisation OMCL Network & Healthcare (DBO)
Department of Biological Standardisation OMCL Network & Healthcare (DBO) Implementation of Pathogen Reduction Technologies for Blood Components for Transfusion: Updated Table 2009-2010 COUNCIL OF EUROPE
PRESS RELEASE ISSUED BY THE STATE UNIVERSITY OF NEW YORK AT ALBANY
PRESS RELEASE ISSUED BY THE STATE UNIVERSITY OF NEW YORK AT ALBANY EMBARGOED FOR RELEASE AT 6:00A.M. EST, FEBRUARY 20, 2001. NOTE TO EDITORS These results will be presented today (Tuesday, February 20,
LEBANON. WCPT COUNTRY PROFILE December 2018
LEBANON WCPT COUNTRY PROFILE December 2018 LEBANON NUMBERS 1600 1400 1200 1000 800 600 400 200 0 Physical therapists in the country Members in MO 1,480 1,480 Total PTs in country 800000 700000 600000 500000
Nutrient profiles for foods bearing claims
Nutrient profiles for foods bearing claims Fields marked with * are mandatory. Background Regulation (EC) 1924/2006 (Nutrition and Health Claims NHC Regulation) establishes EU rules on nutrition and health
DENMARK. WCPT COUNTRY PROFILE December 2018
DENMARK WCPT COUNTRY PROFILE December 2018 DENMARK NUMBERS 14000 12000 10000 8000 6000 4000 2000 0 Physical therapists in the country Members in MO 11,720 12,975 Total PTs in country 800000 700000 600000
Where we stand in EFORT
Where we stand in EFORT Engaging with the new EU regulatory landscape for medical devices. Challenges & opportunities Brussel, Belgium April 6, 2018 Per Kjaersgaard-Andersen Associate Professor Section
Trichinellosis SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods
Annual Epidemiological Report for 2015 Trichinellosis Key facts In 2015, a total of 156 confirmed cases of trichinellosis was reported from 29 EU/EEA countries. The overall notification rate was 0.03 cases
Finnish international trade 2017 Figures and diagrams. Finnish Customs Statistics
Finnish international trade 217 Figures and diagrams Finnish Customs Statistics IMPORTS, EXPORTS AND TRADE BALANCE 199-217 Billion e 7 6 5 4 3 2 1-1 9 91 92 93 94 95 96 97 98 99 1 2 3 4 5 6 7 8 9 1 11
Finnish international trade 2017 Figures and diagrams. Finnish Customs Statistics
Finnish international trade 217 Figures and diagrams Finnish Customs Statistics IMPORTS, EXPORTS AND TRADE BALANCE 199-217 Billion e 7 6 5 4 3 2 1-1 9 91 92 93 94 95 96 97 98 99 1 2 3 4 5 6 7 8 9 1 11
Alcohol-related harm in Europe and the WHO policy response
Alcohol-related harm in Europe and the WHO policy response Lars Moller Programme Manager World Health Organization Regional Office for Europe Date of presentation NCD global monitoring framework: alcohol-related
Drinking guidelines used in the context of early identification and brief interventions in Europe: overview of RARHA survey results
Drinking guidelines used in the context of early identification and brief interventions in Europe: overview of RARHA survey results E. Scafato, C. Gandin, L. Galluzzo, S. Ghirini, S. Martire Istituto Superiore
GERMANY. WCPT COUNTRY PROFILE December 2018
GERMANY WCPT COUNTRY PROFILE December 2018 GERMANY NUMBERS 160000 140000 120000 100000 80000 60000 40000 20000 0 Physical therapists in the country Members in MO 21,502 136,000 Total PTs in country 800000
Q1 What age are you?
Q1 What age are you? Answered: 504 Skipped: 0 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 4.56% 23 3.77% 19 4.56% 23 6.15% 31 3.97% 20 6.55% 33 5.95% 30 6.75% 34 6.35% 32 4.37% 22 6.75% 34 5.56%
Package leaflet: Information for the user Arlevert 20 mg/40 mg tablets cinnarizine/dimenhydrinate
Package leaflet: Information for the user Arlevert 20 mg/40 mg tablets cinnarizine/dimenhydrinate Read all of this leaflet carefully before you start taking this medicine because it contains important
Outcome of proficiency test on EIA serology
Outcome of proficiency test on EIA serology Anses Dozulé Laboratory for equine diseases VIPARE unit Delphine Gaudaire EIA PT GENERAL INFORMATION AIM OF THE PT Detect EIA antibodies: using Agar Gel Immuno-Diffusion
European Community Pharmacy: a reference in Public Health
European Community Pharmacy: a reference in Public Health Ilaria Passarani PGEU Secretary General 4 October 2018, Burgos, Spain Pharmaceutical Group of European Union Members: Professional Bodies & Pharmacists
Engagement in language assessment / Regions of Europe
Summary table: Engagement in language / Regions of This table lists the statistically significant differences in the engagement in activities by the respondents from different s of : If the word or appears
Rheumatoid Arthritis Disease Burden and Access to Treatment
Berlin, April 2012 Rheumatoid Arthritis Disease Burden and Access to Treatment Gisela Kobelt, PhD Visiting Professor, Lund University (Sweden) President, European Health Economics (France) Disclaimers
MEDICINES SHORTAGES PGEU GPUE. John Chave - Secretary general. Pharmaceutical Group of European Union Groupement Pharmaceutique de l Union Européenne
MEDICINES SHORTAGES John Chave - Secretary general Members: Professional Bodies & Pharmacists Associations 2013: 32 Countries Austria Belgium Bulgaria Bosnia Herzegovina Cyprus Czech Rep Denmark Estonia
TEDDY. Teddy Network of Excellence. Annagrazia ALTAVILLA. Ph.D. Sciences Ethics LL.M. Health Law. diterranée
Teddy Network of Excellence Annagrazia ALTAVILLA TEDDY Task-force in Europe for Drug Development for the Young Ph.D. Sciences Ethics LL.M. Health Law Associated Senior Lecturer Université de la MéditerranM
Where do EU Contries set the limit for low risk drinking.
Where do EU Contries set the limit for low risk drinking. Results from the EU RARHA survey E. Scafato,L. Galluzzo, S. Ghirini, C. Gandin Istituto Superiore di Sanità, Italy WP5: Outline of the work (tasks)
Trends in injecting drug use in Europe
Trends in injecting drug use in Europe Linda Montanari, Bruno Guarita and Danica Thanki Annual Expert Meeting on Drug-Related Infectious Diseases Lisbon, 15-17 October Overview of the presentation 1) Information
INN Product name Strength Pharmaceutical form
Annex I List of the names, pharmaceutical (s), strength(s) of the medicinal product(s), route(s) of, marketing authorisation (s) in the member states 1 Targin 10 mg/5 mg prolongedrelease Targin 20 mg/10
The cancer burden in the European Union and the European Region: the current situation and a way forward
The cancer burden in the European Union and the European Region: the current situation and a way forward Presented by Zsuzsanna Jakab WHO Regional Director for Europe Informal Meeting of Health Ministers
Overall survival: 1 st line therapy
1 3 Overall survival: 1 st line therapy 2-year OS phase III studies mm Prices per month of oncology medicin Bloomberg Business weekly 26 Feb 2015 Presented By Veena Shankaran at 2016 ASCO Annual Meeting
MENTAL HEALTH CARE. OECD HCQI Expert meeting 17 th of May, Rie Fujisawa
MENTAL HEALTH CARE OECD HCQI Expert meeting 17 th of May, 2013 Rie Fujisawa Mental health indicators Any hospital readmissions for patients with schizophrenia Same hospital readmissions for patients with
Manuel Cardoso RARHA Executive Coordinator Public Health MD Senior Advisor Deputy General-Director of SICAD - Portugal
Manuel Cardoso RARHA Executive Coordinator Public Health MD Senior Advisor Deputy General-Director of SICAD - Portugal Public Health Public health is the science and art of preventing disease, prolonging
(Invented) Name Strength Pharmaceutical form
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1 Member State Austria Austria Austria
REPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE OF THE REGIONS
EUROPEAN COMMISSION Brussels, 17.6.011 COM(011) 35 final REPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE OF THE REGIONS
Package leaflet: Information for the user
Package leaflet: Information for the user Sevelamer Carbonate Rowex 800mg Film-coated tablets sevelamer carbonate Read all of this leaflet carefully before you start taking this medicine because it contains
Research paper: Legal treatment of the use of cannabis for medical purposes in the member states of the European Union
Parliament of Montenegro Parliamentary Institute Research Centre Research paper: Legal treatment of the use of cannabis for medical purposes in the member states of the European Union Podgorica, December
508 the number of suicide deaths in deaths per 100,000 people was the suicide rate in Suicide deaths in 2013 by gender
An overview of suicide statistics This document summarises information about suicide deaths in New Zealand covering up to 13. It does not attempt to explain causes of suicidal behaviour or causes of changes
National Food Chain Safety Office. Directorate of Veterinary Medicinal Product 1107 Budapest, Szállás u. 8. Hungary MUTUAL RECOGNITION PROCEDURE
National Food Chain Safety Office Directorate of Veterinary Medicinal Products 8 Szállás Str., H-1107 Budapest Tel: +36-1/433-0330 Fax: +36-1/262-2839 www.nebih.gov.hu National Food Chain Safety Office
The health economic landscape of cancer in Europe
1 Approval number The health economic landscape of cancer in Europe Bengt Jönsson, Professor Emeritus of Health Economics Stockholm School of Economics 2 Disclaimer This presentation was developed by Professor
Package leaflet: Information for the user. Lescol 20 and 40 mg hard capsules. Fluvastatin
Package leaflet: Information for the user Lescol 20 and 40 mg hard capsules Fluvastatin Read all of this leaflet carefully before you start taking this medicine, because it contains important information
Media Release. Inaugural study reveals that more than one in four women in European and Central Asian prisons locked up for drug offences
Media Release Embargoed 00.01 CET Monday 12 th March 2012 Inaugural study reveals that more than one in four women in European and Central Asian prisons locked up for drug offences Up to 70 percent of
UK bowel cancer care outcomes: A comparison with Europe
UK bowel cancer care outcomes: A comparison with Europe What is bowel cancer? Bowel cancer, which is also known as colorectal or colon cancer, is a cancer that affects either the colon or the rectum. The
Biology Report. Is there a relationship between Countries' Human Development Index (HDI) level and the incidence of tuberculosis?
Biology Report Is there a relationship between Countries' Human Development Index (HDI) level and the incidence of tuberculosis? Introduction Tuberculosis is a serious disease caused by the bacterium Mycobacterium
Package Leaflet: Information for the Patient. FOSRENOL 750 mg oral powder. FOSRENOL 1000 mg oral powder. lanthanum
Package Leaflet: Information for the Patient FOSRENOL 750 mg oral powder FOSRENOL 1000 mg oral powder lanthanum Read all of this leaflet carefully before you start taking this medicine because it contains
National Institute on Alcohol Abuse and Alcoholism. Environmental Approaches
Environmental Approaches Consumption of 10+ and 21+ Drinks on an Occasion At Least Once in the Past Year, 2013 30 25 20 15 10+ drinks 15 25 10+ drinks 16 25 10 5 0 21+ drinks 3 2 21+ drinks 18-20 21-24
Injecting trends in Austria including results of a systematic literature review on interventions aiming to influence the route of administration
Injecting trends in Austria including results of a systematic literature review on interventions aiming to influence the route of administration Alexander Grabenhofer-Eggerth TDI expert meeting - Lisbon,
31 countries (117 registries, 20 national) Increased coverage in countries with regional registries 50% European population Overall >20 million
31 countries (117 registries, 20 national) Increased coverage in countries with regional registries 50% European population Overall >20 million cancer cases Adult patients (age 15+) 45 major cancer sites
Who is a migrant? 12/10/2018. HIV and migrants. Heterogeneous groups of persons with different migration drivers
HIV and migrants Julia del Amo has received research grants awarded to her institution from Companies BMS, Gilead, ViiV and epidemiology teaching fees from ViiV, Gilead and MSD Dr Julia del Amo National
This document is a preview generated by EVS
TECHNICAL REPORT RAPPORT TECHNIQUE TECHNISCHER BERICHT CEN/TR 17223 March 2018 ICS 03.100.70; 11.040.01 English version Guidance on the relationship between EN ISO 13485: 2016 (Medical devices - Quality
Package leaflet: Information for the user
Package leaflet: Information for the user Femara 2.5 mg film-coated tablets letrozole Read all of this leaflet carefully before you start taking this medicine because it contains important information
'SECTION B EU PARTY. The following abbreviations are used:
'SECTION B EU PARTY The following abbreviations are used: AT Austria BE Belgium BG Bulgaria CY Cyprus CZ Czech Republic DE Germany DK Denmark ES Spain EE Estonia EU European Union, including all its Member
Inequalities in health: challenges and opportunities in Europe Dr Zsuzsanna Jakab WHO Regional Director for Europe
Inequalities in health: challenges and opportunities in Europe Dr Zsuzsanna Jakab WHO Regional Director for Europe 21st Congress of the European Association of Dental Public Health 1 October 2016 Budapest
European Status report on Alcohol and Health
European Status report on Alcohol and Health Dr Lars Moller Regional Advisor a.i. WHO Regional Office for Europe Main killers in the WHO European Region Source: Preventing chronic diseases. A vital investment.
The Risk of Alcohol in Europe. Bridging the Gap June 2004
The Risk of Alcohol in Europe Bridging the Gap 16-19 June 2004 1. What is the relationship between alcohol and the risk of heart disease? 2. What is the relationship between alcohol and the risk of other
The Identification of Food Safety Priorities using the Delphi Technique
The Identification of Food Safety Priorities using the Delphi Technique Gene Rowe & Fergus Bolger, GRE 58th Advisory Forum Meeting, Luxembourg, 8-9 December 2015 EU RISK ASSESSMENT AGENDA (RAA) where priorities
Please note that this draft Annex I will be updated to amend information on concerned products/mahs
22 March 2018 EMA/197481/2018 Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, routes of, applicants, marketing authorisation holders in the member states for for omega-3
SOITC Press Ad FAQs. Q: When will these Terms and Conditions changes come into effect?
SOITC Press Ad FAQs Q: Why are AIB changing their services and charging options? A: With the Payment Services Directive II (PSD2) coming into force in 13 th January 2018, AIB are taking this opportunity
European status report on alcohol and health Leadership, awareness and commitment
European status report on alcohol and health 2014 Leadership, awareness and commitment Leadership, awareness and commitment Background Strong leadership from national and local governments is essential
Package Leaflet: Information for the Patient. FOSRENOL 750 mg chewable tablets. FOSRENOL 1000 mg chewable tablets. lanthanum
Package Leaflet: Information for the Patient FOSRENOL 250 mg chewable tablets FOSRENOL 500 mg chewable tablets FOSRENOL 750 mg chewable tablets FOSRENOL 1000 mg chewable tablets lanthanum Read all of this
Global Trade in Lightweight Coated Writing Paper TradeData International Pty Ltd (www.tradedata.net) Page 1 5/18/2015
Page 1 5/18/2015 An Analysis of Global Trade in Lightweight paper, coated with inorganic substances, used for writing etc., of which more than 10% by weight of total fibre content consists of fibres obtained
4,0 g/0,5 g. 2g/250 mg. 4 g/500 mg. 4g/0,5g 2.25 G/VIAL. injection 4.5 G/VIAL. injection. injection
ANNEX I List of the names, pharmaceutical forms, strengths of the medicinal products, route of, marketing authorisation holders in the Member States 1 Route of ) Austria Bulgaria Cyprus Cyprus Czech Republic
Table 6.1 Summary information for colorectal cancer in Ireland,
6 Colorectal cancer 6.1 Summary Colorectal cancer is the second most common cancer in Ireland (excluding non-melanoma skin cancer). It accounts for 12% of all malignant neoplasia in females and 15% in
A report on the epidemiology of selected vaccine-preventable diseases in the European Region 30% 20% 10%
% of reported measles cases WHO EpiBrief A report on the epidemiology of selected vaccine-preventable diseases in the European Region No. /17 This issue of WHO EpiBrief provides an overview of selected
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Eurican DHPPi 2 -L multi Lyophilisate and suspension for suspension for injection. (for Bulgaria, Croatia, Cyprus,
Men & Health Work. Difference can make a difference Steve Boorman & Ian Banks RSPH Academy 2013
Men & Health Promotion @ Work Difference can make a difference Steve Boorman & Ian Banks RSPH Academy 2013 Difference can make a Difference Mens health: State of mens health Use of services Role of the